Constellation Pharmaceuticals (NASDAQ:CNST) Upgraded to Buy by ValuEngine

Constellation Pharmaceuticals (NASDAQ:CNST) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.

A number of other analysts have also issued reports on the company. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Constellation Pharmaceuticals in a report on Wednesday, June 5th. Zacks Investment Research lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, July 15th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $17.29.

Shares of CNST traded down $0.39 during mid-day trading on Thursday, reaching $8.68. The company’s stock had a trading volume of 38,525 shares, compared to its average volume of 39,532. The company has a fifty day moving average price of $9.89. The company has a market cap of $224.03 million and a P/E ratio of -1.74. Constellation Pharmaceuticals has a 1 year low of $4.01 and a 1 year high of $14.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.92 and a current ratio of 6.92.

Constellation Pharmaceuticals (NASDAQ:CNST) last released its earnings results on Wednesday, May 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.05. Sell-side analysts predict that Constellation Pharmaceuticals will post -3.12 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA lifted its holdings in shares of Constellation Pharmaceuticals by 4,092.4% in the first quarter. BNP Paribas Arbitrage SA now owns 3,312 shares of the company’s stock valued at $45,000 after purchasing an additional 3,233 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Constellation Pharmaceuticals by 16.9% in the fourth quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,987 shares in the last quarter. Wade G W & Inc. purchased a new stake in shares of Constellation Pharmaceuticals in the first quarter valued at $166,000. Northern Trust Corp lifted its holdings in shares of Constellation Pharmaceuticals by 12.4% in the fourth quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock valued at $204,000 after purchasing an additional 5,624 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Constellation Pharmaceuticals in the first quarter valued at $221,000. Institutional investors own 64.38% of the company’s stock.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Further Reading: Why are gap-down stocks important?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.